
Topic
Prior Authorization
Documentation, step edits, renewal cycles, appeals, and how payer criteria shape real-world drug use.

Pricing & Access· May 25, 2026 · 9 min read
By Ran Chen#CGRP#CNS and Migraine#Coverage Access

Pricing & Access· May 25, 2026 · 9 min read
PCSK9 inhibitor access landscape: Repatha, Praluent, Leqvio, and Lerochol in 2026
By Ran Chen#PCSK9#Cardiovascular#Coverage Access

Pricing & Access· May 24, 2026 · 12 min read
IL-23 inhibitor access landscape: Skyrizi, Stelara, Tremfya, Omvoh, and Ilumya in 2026
By Ran Chen#Immunology#IL-23 Inhibitor#Coverage Access

Pricing & Access· May 24, 2026 · 12 min read
JAK inhibitor access landscape: Rinvoq, Xeljanz, Olumiant, Leqselvi, and Cibinqo in 2026
By Ran Chen#JAK Inhibitor#Immunology#Coverage Access

Pricing & Access· May 24, 2026 · 11 min read
SGLT2 inhibitor access landscape in 2026

Pricing & Access· May 23, 2026 · 10 min read
DOAC access landscape: Eliquis, Xarelto, Pradaxa, and Savaysa in 2026
By Ran Chen#DOAC#Coverage Access#Prior Authorization

Pricing & Access· May 23, 2026 · 9 min read
Trulicity coverage guide: formulary tiers, prior authorization, and patient assistance
By Ran Chen#GLP-1#Coverage Access#Prior Authorization

Pricing & Access· May 22, 2026 · 10 min read
AI-generated payer policies and restrictive label criteria

Specialty· May 22, 2026 · 13 min read
Benefit verification for specialty drugs: medical vs pharmacy benefit

Specialty· May 22, 2026 · 12 min read